Experienced biotechnology executive Dr Megan Baldwin is set to strengthen the Race Oncology Ltd (ASX:RAC, OTC:RAONF) board as an independent non-executive.
Dr Baldwin, whose appointment will be made effective on January 1, 2025, brings 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications including extensive experience in cancer therapies.
“We are delighted to welcome Dr Megan Baldwin to our board as an Independent (LON:IOG) non-executive director. She brings to the role an exceptional depth of experience in biotechnology and therapeutic drug development," Race executive chair Dr Pete Smith said.
“Megan’s leadership at Opthea, steering the company through its global Phase 3 trials, reflects her visionary approach to addressing critical unmet medical needs. We look forward to leveraging her expertise and insights to help drive the future success of Race.”
Dr Megan Baldwin will strengthen Race Oncology's board.
Visionary approach
Dr Baldwin is the founder and chief innovation officer of Opthea Ltd (ASX:OPT), a late-stage biopharmaceutical company focused on developing novel therapies to address unmet needs in the treatment of retinal eye diseases.
She previously served as CEO and MD of Opthea for 10 years, advancing the company’s lead asset from preclinical studies to global Phase 3 registrational trials.
During her tenure, she oversaw significant capital-raising initiatives, including an A$180 million initial public offering (IPO) and a successful listing on the US Nasdaq exchange.
Before joining Opthea, Dr Baldwin worked at Genentech (now Roche) as a researcher and later transitioned into the company’s commercial division.
Her experience in oncology drug development spans preclinical and clinical investigation of angiogenesis inhibitors targeting tumour growth and metastasis as well as managing competitive intelligence strategies to support Genentech’s early-stage oncology programs.
In addition to her executive leadership roles, she has extensive corporate governance experience. She currently serves on the boards of Anaxis Pharma and Gertrude Biomedical and is a director of AusBiotech.
She holds a Doctor of Philosophy (PhD) in Medicine from the University of Melbourne, where she conducted her doctoral research at the Ludwig Institute for Cancer Research.